Efficacy and Safety of Baricitinib in Active Sjögren disease: A Multicenter, Randomized, Controlled Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #421; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Baricitinib demonstrated superior efficacy over hydroxychloroquine in reducing disease activity and improving systemic and serological parameters in patients with active SjD, with a favorable safety profile. These findings support baricitinib as a promising therapeutic option for this patient population. Figure."
Clinical • Sjogren's Syndrome
|